Back to search

Article

Efficacy and Safety of PD-1/PD-L1 plus CTLA-4 antibodies +/− Other Therapies in Lung Cancer: A Systematic Review and Meta-Analysis

2020-01-10

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Immune checkpoint inhibitors have brought hope for patients with advanced lung cancer, among which PD-1/PD-L1 and CTLA-4 inhibitors have achieved considerable results. This meta-analysis aims to investigate the efficacy and safety of PD-1/PD-L1 combined with CTLA-4 antibodies in patients with advanced lung cancer. <h4>Materials and Methods</h4> Randomized controlled trials (RC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9d3ddd07-caff-5617-9c90-44c94ddd6bec
DOI
10.1101/2020.01.08.20016915
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and Safety of PD-1/PD-L1 plus CTLA-4 antibodies +/− Other Therapies in Lung Cancer: A Systematic Review and Meta-AnalysisDOI 10.1101/2020.01.08.20016915
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Subgroup-Level Network Meta-Analysis for the Efficacy of First-Line Immunotherapy-Based Treatments in Advanced Non-Small Cell Lung CancerSemantic proximity
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity
Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity
The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.Semantic proximity
Toxicities of PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective studySemantic proximity
Select a neighboring publication to make it the new centre.